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Abstract: The main objective of this study was to optimize and characterize a drug delivery 
carrier for doxorubicin, intended to be intravenously administered, capable of improving the 
therapeutic index of the chemotherapeutic agent itself, and aimed at the treatment of pancreatic 
cancer. In light of this goal, we report a robust one-step method for the synthesis of dicarboxylic 
acid-terminated polyethylene glycol (PEG)-gold nanoparticles (AuNPs) and doxorubicin-loaded 
PEG-AuNPs, and their further antibody targeting (anti-Kv11.1 polyclonal antibody [pAb]). 
In in vitro proof-of-concept studies, we evaluated the influence of the nanocarrier and of the 
active targeting functionality on the anti-tumor efficacy of doxorubicin, with respect to its 
half-maximal effective concentration (EC
50
) and drug-triggered changes in the cell cycle. Our 
results demonstrated that the therapeutic efficacy of doxorubicin was positively influenced not 
only by the active targeting exploited through anti-Kv11.1-pAb but also by the drug coupling 
with a nanometer-sized delivery system, which indeed resulted in a 30-fold decrease of doxoru-
bicin EC
50
, cell cycle blockage, and drug localization in the cell nuclei. The cell internalization 
pathway was strongly influenced by the active targeting of the Kv11.1 subunit of the human 
Ether-à-go-go related gene 1 (hERG1) channel aberrantly expressed on the membrane of 
pancreatic cancer cells. Targeted PEG-AuNPs were translocated into the lysosomes and were 
associated to an increased lysosomal function in PANC-1 cells. Additionally, doxorubicin 
release into an aqueous environment was almost negligible after 7 days, suggesting that drug 
release from PEG-AuNPs was triggered by enzymatic activity. Although preliminary, data 
gathered from this study have considerable potential in the application of safe-by-design nano-
enabled drug-delivery systems (ie, nanomedicines) for the treatment of pancreatic cancer, a 
disease with a poor prognosis and one of the main current burdens of today’s health care bill 
of industrialized countries.
Keywords: PEGylated gold nanoparticles, doxorubicin, potassium channel targeting, hERG1, 
pancreatic cancer, antibody-drug conjugate
Introduction
Chronic diseases, such as cancer, are a major contributor of the current health care 
costs of industrialized countries, amounting to around €700 billion in Europe alone.1 
Risk factors like an aging population2 indicate that the incidence of such chronic 
diseases will keep rising. Looking to the future, countries therefore need to find solu-
tions to pressing demographic challenges, such as increased incidence of cancer,3 
that are impacting the health and social spending. Despite regulatory issues and 
technical/scientific challenges,4 cancer nanomedicine – for instance miniaturized 
delivery systems – aiming at improving the therapeutic efficacy of currently available 
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chemotherapeutic agents represents one of the most prom-
ising opportunities for driving a positive balance between 
health care spending austerity and excellent care. Very 
recently, the first nanomedicine – nanoparticle albumin-
bound paclitaxel, named nab-PTX – received approval as 
the first-line treatment of advanced pancreatic cancer in 
combination with gemcitabine.5,6
Gold nanoparticles (AuNPs) are attracting consider-
able interest as viable materials for cancer nanomedicine.7,8 
Aurimune (CYT-6091)9 is the most famous example of gold 
nano-enabled product currently used in clinical settings for 
cancer treatment. It consists of PEGylated (polyethylene 
glycol) AuNPs that safely drive the delivery of tumor necrosis 
factor-alpha, a potent vascular disruptive agent, to tumor site. 
Phase-I clinical trial of Aurimune has provided encourag-
ing data on its safety and efficient accumulation to tumor 
site.10 Phase II clinical trials have been announced (http://
www.cytimmune.com/user/register#pipeline).11 Several 
other gold-chemotherapy agents, such as Auroshell12,13 and 
Aurimune, are under clinical trials or seeking approval.9,10,12–14 
Noteworthy, at the beginning of 2013, the international 
pharmaceutical company AstraZeneca in partnership with 
CytImmune focused on developing a cancer nanomedicine 
based on AuNPs.15
The successful application of AuNPs as tools for cancer 
treatment is mainly associated to their unique physico-
chemical properties and acceptable biocompatibility.16,17 The 
chemical properties of AuNPs surface are among the many 
advantages of AuNPs over other organic and inorganic nano-
counterparts. The functionalization of AuNPs surface is in 
fact easy and highly controllable; thus, the surface chemistry 
and hydrodynamic diameter of AuNPs, as well as their 
pharmacokinetics and biodistribution, can be appropriately 
tailored through a safe-by-design approach.11,16,18,19 The use 
of biomolecules to tune the surface properties and assembly 
of AuNPs is also a very attractive approach that has received 
considerable attention. For instance, biomolecule- and/or 
biopolymer-conjugated AuNPs are widely used for bio-
markers’ detection,20 delivery systems,8 and theranostics21 
in medicine/pharmaceutical fields, as well as components of 
cosmetic products.22 Similarly, the safety profile of AuNPs 
can be finely tuned by modifying the size and/or composition 
of the gold nanocarrier. Studies on AuNPs showed that these 
nanomaterials do not accumulate in the liver and do not elicit 
long-term hepatic dysfunction in animal models.23,24 Data on 
the clearance of PEGylated gold nanomaterials also showed 
that once accumulated, gold nanocarriers were gradually 
cleared from the body.24 In addition, as recently demonstrated 
by some of the authors of this study,16 gold nanocarriers can 
be degraded within the cells. Finally, gold nanomaterials 
have enormous potential as multimodal agents. AuNPs are 
in fact excellent labels for real-time in vivo imaging and/or 
probes for photothermal therapy.
Currently, despite the broad interest and efforts sur-
rounding gold-based nanomedicines, their clinical transla-
tion rate does not comply with predictive market studies. 
This is indeed linked to the technical challenges associated 
with the synthesis and formulation of gold nanomedicine. 
In the past decades, many synthetic strategies have been 
developed to prepare colloidal AuNPs in organic or aque-
ous solvent.7,25 One of the most common methods employed 
for the synthesis of gold nanomaterials involves the use of 
cetyl-tetra ammonium bromide, a cationic surfactant.26,27 
In parallel to cetyl-tetra ammonium bromide, a variety of 
stabilizers have been employed for the synthesis of AuNPs 
to date.17,27–29 Stabilizers can be usefully exploited to prevent 
particles aggregation while tuning the functional properties 
of the nanomaterial produced. Nevertheless, most of these 
stabilizers are toxic, which is a matter of concern for clinical 
applications and regulatory requirements. Removal of excess 
stabilizer causes, on the other side, unwanted aggregation 
of the particles, thus negatively influencing the stability and 
bioavailability of the nanomedicines synthesized. Recently, 
some authors reported a one-step synthesis approach to pre-
pare polymer-modified AuNPs using dicarboxylic polyethyl-
ene glycol (PEG) as stabilizer.30 As a significant development 
of such study, in this work, we report a robust strategy for 
synthesizing stable PEG-AuNPs loaded with an antican-
cer drug associated with dose-limiting severe side effects 
(doxorubicin, DOX) and decorated with an anti-Kv11.1 
polyclonal antibody (anti-Kv11.1-pAb) as active targeting 
functionality (Figure 1). The anti-Kv11.1-pAb specifically 
recognizes surface biomarkers (namely human ether-à-go-go 
related gene 1 [hERG1] K+ channels) aberrantly expressed 
on the cell membrane of pancreatic ductal adenocarcinoma 
(PDAC) cells.31 Given that inter- and intra-tumor variabil-
ity can affect the architecture of the tumor vascularization/
microenvironment and, consequently, the passive targeting 
efficacy,32 the active targeting strategy exploited herein 
through anti-Kv11.1-pAb is envisaged to capitalize on the full 
potential benefit of the nanomedicine developed. Although it 
is accepted that the enhanced permeation and retention (EPR) 
effect aids to nanoparticles’ passive targeting of tumors, the 
effectiveness of such targeting strategy can be affected by 
several factors.33 The particularly abundant desmoplastic 
stroma of PDAC34,35 has been recognized as a key player 
in acting as a physical barrier to drug diffusion36 (from the 
blood vessels to the cancer cells) and as a mechanical barrier 
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wide range of spectroscopic and physicochemical techniques. 
In parallel, toxicity and therapeutic indexes of PEG-AuNPs 
were evaluated in proof-of-concept (PoC) in vitro studies 
by means of a high throughput screening based on flow 
cytometry. A high throughput screening approach, coupled to 
laser scanning confocal microscopy (LSCM), was also used 
to identify the pathways involved in the cell internalization 
of PEG-AuNPs. Our results demonstrated that the synthetic 
procedure proposed herein can be successfully used for 
producing a gold nanomedicine of the highest quality with 
potential clinical application in PDAC treatment.
Materials and methods
Materials
Tetrachloroauric acid (HAuCl
4
), sodium borohydride (NaBH
4
), 
N-hydroxysuccinimide (NHS), 1-(3-dimethylaminopropyl)-
N′-ethylcarbodiimidehydrochloride (EDC), cysteamine 
(CYS), ethanol (Normapur 99%), phosphate-buffered solu-
tion (PBS), PEG-600 diacid, doxorubicin hydrochloride, 
and anti-Kv11.1 extracellular pAb were purchased from 
Sigma-Aldrich (St Louis, MO, USA). All solvents were 
reagent-grade and used without any further purification. 
Experiments were carried out at room temperature if not 
specified otherwise.
synthesis of Peg-aunPs
synthesis of auPeg_1
Colloids of COOH-terminated PEG-coated AuNPs 
(AuPEG_1) were prepared according to previously described 
procedure (Figure 2).38 Briefly, 20 mL of chloroauric acid 
(HAuCl
4
) aqueous solution (2.5×10-4 M) was added to 
0.25  mL of dicarboxylic PEG and mixed by magnetic stirring 
for 10 minutes at room temperature. To this solution, 6 mL 
of aqueous 0.01 M NaBH
4
 was added at once. The color of 
the dispersion indeed instantly changed from yellow to red 
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Figure 1 schematic representation of Peg-aunPs chemical structures.
Note: Drawings are not in scale and are not intended as representative of the full 
sample composition.
Abbreviation: Peg-aunPs, polyethylene glycol-gold nanoparticles.
to drug perfusion37 (through blood vessels), thus hindering 
chemotherapy delivery to PDAC cells. In light of this, the 
working hypothesis behind this study focused on an active 
targeting strategy.
Assembly and functionalization of PEG-AuNPs, as well 
as antibody grafting, were monitored by a combination of a 
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Figure 2 synthesis of auPeg_1.
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when sodium borohydride was added to a solution of gold 
precursor in the presence of PEG-diacid polymer, confirming 
the formation of AuPEG_1 in the solution. The as-prepared 
PEG-Au NP solution was purified by centrifugation and 
dialysis to remove excess of non-conjugated dicarboxylic 
PEG.39 Centrifugation was carried out at 15,000 rpm for 
26 minutes for three times and then the supernatant was dis-
carded. The residue was redispersed in an equivalent amount 
of PBS (pH=7). This was repeated twice.
Doxorubicin loading onto auPeg_1 and formation 
of auPeg_3
Conjugation of DOX to AuPEG_1 surface was carried out as 
from previous published work,38,40,41 using a carbodiimide-based 
conjugation of the carboxylic-terminated polymer and forming 
AuPEG_3. Briefly, 20 μL of EDC/NHS (80/20 mg ratio) aque-
ous solution was added to 5 mL of AuPEG_1. After 2 hours, 
DOX (1 mL, 1.72×10-4 M) was added and aged for 2 hours. 
The reaction mixture was then centrifuged three times and 
redispersed in PBS to remove any unbound DOX. The encap-
sulation efficiency (percentage of DOX bound to nanoparticles) 
was calculated as the difference between the initial drug content 
and the amount of free DOX in the filtrate after separation of the 
nanoparticles by ultrafiltration (Ultrafree MC centrifugal filter 
units, 30,000 NMWL; Merck Millipore, Darmstadt, Germany). 
The reaction efficiency was equal to 80%.
anti-Kv11.1-pab immobilization onto auPeg_1 and 
auPeg_3 surface
The binding of anti-Kv11.1-pAb onto PEG-AuNPs was 
performed at pH 7.4 in PBS. Briefly, 20 μL of EDC/NHS 
(80/20 mg ratio) aqueous solution was added to 5 mL of 
AuPEG_1 or AuPEG_3 dispersions. After 2 hours, 50 μL 
(0.1 ng/mL) of anti-Kv11.1-pAb in PBS was added to 2 mL of 
the reaction mixture and stirred for 2 hours at room tempera-
ture. The PEG-AuNPs thus obtained were centrifuged two 
times at 9,000 rpm for 30 minutes and dried under nitrogen. 
Figure 3 depicts the synthetic procedure for the conjugation 
of anti-Kv11.1-pAb onto PEG-AuNPs surface. Successful 
grafting of anti-Kv11.1-pAb was monitored by dynamic light 
scattering (Figure S1).
Physicochemical characterization of 
Peg-aunPs
All the measurements were performed in duplicate in order 
to validate the reproducibility of the synthetic procedure.
UV–vis absorption spectroscopy
Absorption spectra were recorded using a double-beam 
Varian Cary 500 UV–Vis spectrophotometer (Agilent, 
Les Ulis, France). Absorption spectra of the PEG-AuNPs 
were recorded water at a concentration of 10-4 M in the 
350–900 nm spectral range.
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Figure 3 conjugation of anti-Kv11.1-pab onto auPeg_1 and auPeg_3 surface, producing auPeg_2 and auPeg_4, respectively.
Note: schematic representation: drawings are not in scale and are not intended as representative of the full sample composition.
Abbreviations: nhs, N-hydroxysuccinimide; eDc, N′-ethylcarbodiimidehydrochloride.
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X-ray photoelectron spectroscopy
Gold surfaces were used as a support for the immobilization 
of AuPEG_1 to verify the better orientation of antibody before 
DOX binding. The schematic diagram showing the chemical 
immobilization method is reported in Figure S2. The chemical 
procedure used for the surface immobilization of PEG-AuNPs, 
based on self-assembled monolayer of cysteamine in absolute 
EtOH, was previously described.30 Briefly, the freshly cleaned 
gold substrate was immersed in an unstirred 10 mM ethanol 
solution of β-mercaptoethylamine (cysteamine) at room tem-
perature in the dark for 6 hours. The gold substrate was then 
washed with EtOH and milli-Q water to remove the excess of 
thiol. A total of 2 mL of PEG-AuNPs was suspended in 2 mL 
of buffer solution (PBS, pH=7), in which 0.5 mEq of EDC/
NHS was added and stirred for 2 hours (preactivation). The 
colloidal solution was deposited on cysteamine-gold-coated 
surface for 12 hours at room temperature.
X-ray photoelectron spectroscopy (XPS) analysis was 
performed using a SPECS (Phoibos MCD 150) spectrometer 
(SPECS, Berlin, Germany) equipped with a monochroma-
tized Al X-ray source (hν =1,486.6 eV) and a Phoibos 150 
hemispherical energy analyzer. Pass energies of 20 eV was 
used for the survey scan and 10 eV for narrow scans.
X-ray diffraction
The X-ray diffraction (XRD) spectra of AuPEG_1 powder sam-
ples were recorded by means of a Siemens D500 diffractometer 
and a Bruker D8 diffractometer (Bruker Corporation, France) 
using Cu Kα radiation (1.5418 Å). This analysis was carried 
out at 40 kV and 100 mA; the scan step size was set at 0.0500° 
and the scan step time was 10 seconds. Theoretical diffraction 
patterns of gold and PEG components were extrapolated from 
the literature data for the corresponding crystal structures.
electron microscopy
Scanning electron microscopy (SEM) images were carried 
out by a SEM FEG Hitachi SU-70 scanning electron micro-
scope (Hitachi, Tokyo, Japan) with a low voltage of 1 kV 
and distance of 1.5–2 mm;  the second electron detector was 
used. A total of 50 μL of colloidal solution was deposited 
onto a clean gold substrate and dried at room temperature 
for the SEM measurements.
Transmission electron microscopy (TEM) images were 
recorded with a JEOL JEM 1011 microscope operating 
(JEOL, Tokyo, Japan) at an accelerating voltage of 100 kV. 
TEM specimens were prepared after separating the surfactant 
from the metal particles by centrifugation. Typically, 1 mL 
of PEG-AuNPs was centrifuged for 20 minutes at a speed 
of 14,000 rpm. The upper part of the colorless solution was 
removed and the solid portion was redispersed in 1 mL of 
water. A total of 2 μL of this redispersed particle suspension 
was placed on a carbon-coated copper grid manufactured by 
Smethurst High-Light Ltd (Elektron Technology, Cambridge, 
UK) and marketed exclusively by Agar Scientific (Essex, 
UK) and dried at room temperature.
Polarization modulation-infrared reflection-adsorption 
spectroscopy
Polarization modulation-infrared reflection-adsorption spec-
troscopy (PM-IRRAS) spectra were acquired by a Thermo 
Nexus spectrometer (Les Ulis, France). Self-assembled 
monolayer of cysteamine followed by PEG-AuNPs grafting, 
as described in the previous sections, was used to immobilize 
AuPEG_2 and AuPEG_4 on gold surfaces. The external beam 
was focused on the sample with a mirror, at an optimal incident 
angle of 80°. ZnSe grid polarizer and ZnSe photoelastic modu-
lator improve the incident beam between p- and s-polarizations 
(HINDS Instruments; Thermo Fischer Scientific Inc., Waltham, 
MA, USA), PEM 90, modulation frequency =37 kHz, were 
placed prior to the sample. The light reflected at the sample 
was then focused onto a nitrogen-cooled Mercury-Cadmium-
Telluride detector. The presented spectra result from the sum 
of 128 scans recorded with an 8 cm-1 resolution.
Zeta potential measurements
The zeta potential of PEG-AuNPs dispersed in water was 
measured using the electrophoretic mode of a Zetasizer 
NANOZS (Malvern Instruments Ltd, Malvern, UK).
nanoparticle tracking analysis
PEG-AuNPs average hydrodynamic diameters in complex 
dispersal media were characterized using nanoparticle 
tracking analysis (NTA) developed by NanoSight (Malvern 
Instruments Ltd). This equipment utilizes the properties 
of light scattering and Brownian motion to obtain particle 
size distributions of samples in liquid suspension.42 PEG-
AuNPs were diluted in PBS and fetal bovine serum (FBS), 
as well as in complete cell culture medium (ie, Dulbecco’s 
Modified Eagle’s Medium [DMEM] supplemented with 10% 
FBS). The latter was included in order to evaluate potential 
interactions between PEG-AuNPs and the environment 
used in in vitro PoC studies. NTA was conducted at time 0 
(directly after dispersion in the complex media) and follow-
ing 24 hours of incubation at 37°C. NTA was carried out by 
means of a NS500 system equipped with a 405 nm laser, with 
NTA version 3.0. Six by sixty seconds videos were recorded 
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at an NP concentration sufficient to obtain a minimum of 200 
completed tracks per video for statistical significance. NTA 
data are reported as mode ± standard deviation.
cell culture
PANC-1 cells, a human pancreatic carcinoma cell line 
aberrantly expressing hERG1 K+ channel,43 were obtained 
from the American Tissue Culture Collection (ATCC). 
No ethical approval was needed for these experiments as 
the cell line used is commercially available and was not 
originated in the lab from human tissue samples. PANC-1 
cells were cultured in DMEM (Gibco, Bio-Sciences Ltd, 
Ireland) supplemented with 10% FBS (Sigma-Aldrich) in 
a humidified atmosphere at 37°C and 5% CO
2
. Cells were 
seeded at a density of 8×104 cells/mL (4×104 cells/well; 
500 μL/well) in a 24-well plate (growth area =1.9 cm2; 
Nunc®; Fisher Scientific, Dublin, Ireland) or in four-well 
glass slides (growth area =1.7 cm2; BD Biosciences, Franklin 
Lakes, NJ, USA). Cells were incubated for 24 h at 37°C 
and 5% CO
2 
to allow the cells to adhere to the substrate. 
Seeding concentrations of 3.5×104 cells/mL (7×103 cells/
well; 200 μL/well) and 105 cells/mL (2×105 cells/well; 
2 mL/well) were used when utilizing 96-well plates (growth 
area =0.32 cm2; Nunc; Fisher Scientific) or six-well plates 
(growth area =9.5 cm2; Nunc; Fisher Scientific) in order to 
keep the cell density consistent among experiments.
lc50 and ec50 determination
PANC-1 cells were exposed to a series of PEG-AuNPs dilu-
tions in complete media (concentrations ranging from 0 to 
2.5×10-4 M; 500 μL/well) or DOX (concentrations ranging 
from 0 to 8 μM) for 24 hours in 24-well plates. Untreated 
cells (negative control) and cells exposed to 70% acetone for 
30 minutes (positive control), as well as cells treated with 
diacid PEG (67.1 μg/mL) for 24 hours, were also included 
in the experimental design. After 24-hours exposure to PEG-
AuNPs, PANC-1 cells were washed with PBS, detached 
from the wells using 200 μL/well TrypLE™ Select (Gibco, 
Bio-sciences), and transferred to Eppendorf tubes containing 
600 μL media. Cell counting was then carried out on the cell 
suspensions by means of BD Accuri® C6 flow cytometer 
(Becton Dickinson Biosciences, Oxford, UK), keeping con-
stant the counting time among samples. Cell population anal-
ysis was performed as per the supplier’s protocol.44 Briefly, 
the cells were visualized using the FSC-A versus FSC-H 
scatter plot and a gate was applied (P1) to exclude debris 
at lower scatter intensities and cell aggregates via doublet 
discrimination. A minimum of 10,000 events was collected 
in the (P1) gate for the negative control. Measurements for 
each sample were carried out in triplicate and are presented 
as average ± standard deviation. Dose–response curves were 
fitted to such data, by applying a dose–response equation 
for inhibition (normalized response) (Prism; Graph-Pad 
Software Inc., La Jolla, CA, USA). Since the logarithmic 
function of 0 is undefined, the zero concentration (negative 
control) was approximated to 10-8 M for PEG-AuNPs and 
0.06 μM for DOX, that is, approximately two log units 
below the lowest “real” log(x) value. Data were normal-
ized to percent of maximal response based on the negative 
control (corresponding to the 100% value). The minimum 
y value, corresponding to the 0% value, corresponded to the 
positive control reading. Half-maximal lethal concentration 
(LC
50
) data for PEG-AuNPs and half-maximal effective 
concentration (EC
50
) of DOX were extrapolated from the 
curves thus obtained.
cell cycle analysis
PANC-1 cells cultured in 24-well plates were exposed 
to PEG-AuNPs for 24 hours at two concentrations that 
resulted to be sub-cytotoxic for AuPEG_1, as determined 
by LC
50
 determination experiments. In detail, the concen-
trations tested were as follows: 1.3×10-5 and 1.9×10-5 M for 
AuPEG_1; 1.4×10-6 and 2×10-6 M for AuPEG_2; 2.5×10-8 
and 4×10-8 M for AuPEG_3 and AuPEG_4. Untreated 
cells (negative control) and cells exposed to 1.5 μM DOX 
(positive control) were also included in the experimental 
design. Possible cell cycle effects caused by exposure to 
the DOX loaded onto AuPEG_3 and AuPEG_4, and/or by 
the AuPEG_1 and AuPEG_2 themselves, were evaluated 
using the BD Cycletest™ Plus DNA Reagent Kit (Becton 
Dickinson Biosciences). Briefly, after 24-hours exposure, 
cells were harvested using TrypLE™ Select (200 μL/well), 
transferred to Eppendorf tubes containing 600 μL media, 
and centrifuged at 4,000 rpm for 5 minutes. Supernatants 
were removed after centrifugation and 1 mL of lysis buffer 
was added, followed by vortexing of each sample (this wash 
step was completed twice). Cell cycle assay was then per-
formed according to the manufacturer’s protocol. Stained 
cells were analyzed using BD Accuri® C6 flow cytometer 
(Becton Dickinson Biosciences). Briefly, the stained nuclei 
were visualized using the SSC-H versus FSC-H scatter plot 
and a gate was applied (P1) to exclude debris at lower scatter 
intensities. Aggregate exclusion gating (P2 in P1) via doublet 
discrimination was then performed on the P1 population 
using the FL2-H versus FL2-A scatter plot. A minimum of 
10,000 events was collected in the (P2 in P1) gate and visu-
alized on the FL2-A histogram. Analysis of cell cycle stage 
for G0/G1, S, and G2/M phase was made by manual gating 
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on the FL2-A histogram. Representative FL2-A histograms 
are shown as percentage (%) cell population in (P2 in P1). 
Mean values are also reported as average ± standard devia-
tion (n
test
=2) in Table S1.
Drug delivery – mechanism
cellular internalization of auPeg_3 and auPeg_4 
and colocalization into lysosomes
PANC-1 cells cultured on four-well glass slides were exposed 
to AuPEG_3 (6.5×10-8 M) or to AuPEG_4 (4.25×10-8 M) for 
24 hours. PANC-1 cells were then washed with prewarmed 
PBS, fixed with 3.7% PFA for 10 minutes at room temperature, 
and permeabilized with 0.1% TritonX-100 for 5 minutes. After 
incubation in blocking buffer (1% bovine serum albumin) for 
1 hour at room temperature, specimens were stained for glyco-
sylated lysosomal-associated membrane protein-1 (LAMP-1) 
with LAMP-1 (D2D11) XP® Rabbit pAb (1:200) (Cell Sig-
nalling Technology Inc., Danvers, MA, USA) overnight at 
4°C. Cells were then washed with PBS and incubated with 
anti-rabbit IgG (H+L), F(ab′)2 fragment (Alexa Fluor 488® 
Conjugate) (1:1,000) (Cell Signalling Technology Inc.) and 
Hoechst 33342 (Invitrogen, Bio-sciences, Dublin, Ireland) for 
nuclei counterstain for 2 hours in the dark at room temperature. 
After washing with PBS, specimens were mounted in transpar-
ent mounting medium (VECTASHIELD; Vector Laboratories 
Inc., Burlingame, CA, USA) prior to LSCM analysis by a 
ZEISS LSM 510 Meta confocal microscope equipped with 
a Zeiss Zen software (Carl Zeiss, Oberkochen, Germany). 
DOX delivery and release was evaluated by monitoring the 
red fluorescence within the cells’ body,45 while PEG-AuNPs 
were imaged in reflectance mode at λ
exc
=561 nm as previ-
ously described.16 In reflectance mode, the scattered light 
is collected under single laser wavelength excitation using 
a confocal microscope. The high scattering cross-sections 
of AuNPs,46–51 together with their superior photostability as 
compared to organic dyes, make their imaging extremely 
easy and accurate.52 LSCM imaging was used as a qualita-
tive technique. The colocalization of LAMP-1 expression 
and PEG-AuNPs was evaluated by using the colocalization 
function of the ZEN software (Carl Zeiss), according to the 
manufacturer’s guidelines.53 Briefly, colocalization analysis 
was performed on a pixel-by-pixel basis. Every pixel in the 
image was plotted in a scatter diagram based on its intensity 
level, where LAMP-1 intensity was selected on the x-axis 
and PEG-AuNPs reflectance intensity was on the y-axis. 
Crosshairs were placed on the scatter diagram so that only 
pixels with intensity levels above 50 au in both channels were 
considered to be colocalized. To set the crosshairs, negative 
(untreated) controls were imaged with the same microscope 
settings as the cells exposed to PEG-AuNPs, to ensure that 
any colocalized pixels were due to significant intensity levels 
of both channels and not from changes in the sample prepa-
ration or acquisition settings. Images masked on colocalized 
pixels are reported.
cell lysis and Western immunoblotting of laMP-1 
protein expression
PANC-1 cells cultured on six-well plates were exposed to 
AuPEG_3 (6.5×10-8 M) or AuPEG_4 (4.25×10-8 M) for 
24 hours. PANC-1 cells were then washed with prewarmed 
PBS and lyzed, followed by the addition of 200 μL/well of 
RIPA lysis buffer system (Santa Cruz Biotechnology Inc., 
Dallas, USA) and incubated for 30 minutes on ice. Lysis 
solution was prepared as per supplier’s instructions. Cells 
were scraped from wells, transferred to Eppendorf tubes, 
and centrifuged at 13,000 rpm for 10 minutes at 4°C. Pro-
tein determination of each lysate sample was determined by 
Pierce BCA Protein Assay Kit (Product no 23227; Thermo 
Scientific) as per supplier’s protocol. The required amount 
of lysate to load 20 μg of protein was transferred to a fresh 
Eppendorf tube and incubated with 1 mL of ice-cold acetone 
for 30 minutes on ice for protein precipitation. Samples were 
then centrifuged at 13,000 rpm for 10 minutes at 4°C. After 
the removal of the supernatant, protein pellets were boiled 
in 2× Laemmli sample buffer for 5 minutes and resolved on 
NuPAGE 4%–12% Bis–Tris Gel (Novex®; Life Technolo-
gies, Fisher Scientific, Dublin, Ireland). Molecular weight 
markers and separated proteins were electrophoretically 
transferred to polyvinylidene difluoride membranes by 
wet transfer for 30 minutes at 500 mAmh. Polyvinylidene 
difluoride membranes were blocked in 5% nonfat dry milk 
in PBST (0.1% Tween 20 in PBS) for 1 hour at room tem-
perature with gentle agitation. Three wash steps (5 minutes 
each) were carried out before incubation with a primary 
antibody against nonglycosylated and glycosylated LAMP-1 
protein (LAMP-1 [C54H11] rabbit mAb, Cell Signalling, 
Brennan & Company, Dublin, Ireland) diluted in 5% bovine 
serum albumin in PBST (1:1,000). Incubation was carried 
out overnight at 4°C with gentle agitation. The membrane 
was then washed three times and incubated with anti-rabbit 
IgG HRP-linked secondary antibody (Cell Signalling, Bren-
nan & Company) in blocking buffer (1:2,000) for 1 hour 
at room temperature. After triple washing in PBST, the 
selected bands were developed using SuperSignal® West 
Pico Chemiluminescent Substrate (Thermo Scientific). 
Exposure to Kodak light-sensitive film allowed the bands 
located at 40 kDa (nonglycosylated LAMP-1) and 100 kDa 
(glycosylated LAMP-1) to be visualized. Results shown 
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are representative of two independent experiments (n
tests
=2 
and n
replicates
=3).
endocytosis pathway
To determine by which transport route(s) AuPEG_3 and 
AuPEG_4 were internalized into cells, PANC-1 cells were 
seeded in 96-well plates and exposed to PEG-AuNPs in the 
presence of 1) an inhibitor of the cellular energy-dependent 
mechanisms of uptake (0.1% sodium azide [NaN
3
]; 1.5 mM; 
3 hours pretreatment), 2) an inhibitor of the receptor-
mediated endocytosis (RME), that is, cells cultured at 4°C, 
3) inhibitors of clathrin-dependent (Pitstop® 2; 12 μM) 
or caveolae-dependent (Filipin III; 5 μg/mL; 30 minutes 
pretreatment) endocytosis, or 4) an inhibitor of the protein 
transport from the endoplasmic reticulum to the Golgi appa-
ratus (Brefeldin A; 500 ng/mL), thus hindering the maturation 
of the hERG1 channels (Figure 4). With exception of the 
experiments at 4°C, where cells were exposed to PEG-AuNPs 
for 4 hours, AuPEG_3 and AuPEG_4 were incubated with 
cells for 6 hours. Since AuPEG_3 and AuPEG_4 effect on 
the cell count was shown to be time-dependent (Figure S3), 
a concentration equal to two times the LC
50
 (corresponding 
to 2.6×10-7 M for AuPEG_3 and 1.7×10-7 M for AuPEG_4) 
was tested to ensure that a significant decrease in cell count 
would be detectable in the absence of inhibitors after 6 hours. 
Negative controls (NT), consisting of PANC-1 cells exposed 
to supplemented cell medium or the inhibitors alone, were 
included in the experimental design. Following exposure, 
PANC-1 cells were washed with prewarmed PBS, fixed 
with 3.7% paraformaldehyde (10 minutes, room tempera-
ture) and stained with Hoechst 33342 for nuclei (Invitrogen, 
Bio-sciences) for 30 minutes at room temperature in the dark. 
After washing with PBS, cells were counted by means of 
high-content screening and analysis (HCSA) based on the 
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Figure 4 schematic of potential cell internalization routes of auPeg_3 and auPeg_4: (i) via energy-dependent endocytosis processes, among which (ii) rMe pathways, 
and/or (iii) by active targeting of the Kv11.1 subunit of the herg1 potassium (K+) channels, which are aberrantly expressed on Panc-1 cells surface.
Notes: Folding and assembly of the hERG1 channels occur in ER. Folded polypeptides are then transported to the Golgi apparatus and mature channels traffic to the cell 
membrane via vesicles. The inhibitors (‘T’ shaped symbols) used for identifying the mechanism by which Panc-1 cells internalized auPeg_3 and auPeg_4 are also depicted. 
aunPs are represented by gray circles, Peg chains by the (~) symbol, DOX by purple stars, and anti-Kv11.1-pab by blue triangles. Please note that drawings are not to scale.
Abbreviations: Peg, polyethylene glycol; rMe, receptor-mediated endocytosis; er, endoplasmic reticulum; DOX, doxorubicin; pab, polyclonal antibody; aunPs, gold 
nanoparticles; auPeg, Peg-coated aunPs; h, hours.
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analysis by In Cell Analyzer 1000, as previously described.16 
Data are reported as average (n
tests
=3 and n
replicates
=3) ± 
standard error of the mean and normalized on the corre-
sponding NT. This normalization was applied to highlight 
how – when the internalization pathway was inhibited – the 
therapeutic effect of PEG-AuNPs (detected as a drop in cell 
viability) was not detectable.
Results
In this study, the synthesis and physicochemical charac-
terization of PEG-AuNPs (AuPEG_1) loaded with DOX 
(AuPEG_3) and targeted with anti-Kv11.1-pAb (AuPEG_4) 
were carried out. Targeted PEG-AuNPs with no drug payload 
(AuPEG_2) were also prepared for comparison.
In vitro PoC data were acquired at the second stage of 
the study to gain an insight into the toxicity (LC
50
) and thera-
peutic (EC
50
) indexes of PEG-AuNPs as nanomedicine with 
application in the PDAC treatment. An in-depth investigation 
of the endocytosis pathway driving AuPEG_3/AuPEG_4 
internalization and drug release was also carried out.
synthesis of Peg-aunPs
Formation of auPeg_1 and auPeg_3
AuPEG_1 and AuPEG_3 were synthesized as described in 
the “Materials and methods” section.
active targeting
AuPEG_1 and AuPEG_3 were used as a support for the 
conjugation of the targeting moiety (anti-Kv11.1-pAb). 
The anti-Kv11.1-pAb was selected as it specifically recog-
nizes the Kv11.1 protein, which is an essential subunit of 
the potassium ion channel encoded by the human hERG1. 
hERG1 K+ channels are overexpressed in several types of 
human cancers,31,54 including PDAC.43 Anti-Kv11.1-pAb 
molecules were immobilized on the surface of activated 
nanoparticles through the formation of amide links between 
the COOH groups decorating the surface of the PEG-AuNPs 
and the NH
2 
groups of the pAb (Figure 3).
Physicochemical characterization of 
Peg-aunPs
UV–vis absorption spectroscopy
The interaction between anti-Kv11.1-pAb and AuPEG_1 
was monitored by detecting changes in the localized sur-
face plasmon (LSP) band typical of the UV–Vis absorption 
spectra of PEG-AuNPs. Figure 5A displays the LSP band of 
PEG-AuNPs before (AuPEG_1) and after (AuPEG_2) immo-
bilization of the anti-Kv11.1-pAb. AuPEG_1 (Figure 5A, 
black line) showed an LSP band centered at ~520 nm, typical 
of AuNPs.27,40 This indeed demonstrated that AuNPs were 
formed following the reduction of AuCl
4
-.40 After immo-
bilization of anti-Kv11.1-pAb onto AuPEG_1 (Figure 5A, 
red line), the resulting solution was colorless and was 
characterized by a broad LSP peak at 812 nm, which could 
be attributed to the change of localized refractive index 
of PEG-AuNPs. It is commonly accepted that the peak 
intensity and position of the LSP band are dependent on the 
size, agglomeration, and shape of AuNPs.55 The significant 
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Figure 5 UV–vis absorption spectra of Peg-aunPs.
Notes: (A) Before (auPeg_1) and after conjugation to anti-Kv11.1-pab (auPeg_2), and (B) before (auPeg_3) and after (auPeg_4) conjugation to anti-Kv11.1-pab.
Abbreviations: Peg, polyethylene glycol; aunPs, gold nanoparticles; auPeg, Peg-coated aunPs.
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red-shift in the LSP position with peak broadening in the 
AuPEG_2 spectra suggested a linear increase in particle 
size consequent with the modification of the nanoparticles 
surface.55,56 Based on the UV–Vis spectrum of AuPEG_2, 
we suggest that such increase could be associated to the 
successful functionalization of the AuNPs surface with 
anti-Kv11.1-pAb and the subsequent AuNPs aggregation 
associated to the formation of classical van der Waals inter-
protein interactions.57
The UV–Vis absorption spectrum of AuPEG_3 
(Figure 5B, black line) displayed an intense band at 483 nm 
and two small peaks at 470 and 533 nm, in good agreement 
with the optical characteristics of the molecular DOX.58 
A strong resonance band at around 748 nm was also detected, 
corresponding to longitudinal plasmon oscillation.59 After the 
conjugation of AuPEG_3 to anti-Kv11.1-pAb (AuPEG_4), 
the resulting solution was colorless, with a decrease in the 
UV–Vis spectrum intensity (Figure 5B, red line) and a 
red-shift of around 20 nm (from 748 to 761 nm) of the LSP 
band. This phenomenon could be attributed to the change 
of localized refractive index near the nanoparticles surface, 
indicating that the anti-Kv11.1-pAb was successfully con-
jugated to the PEG-AuNPs surface.
X-ray photoelectron spectroscopy
XPS analysis clearly evidenced the presence of PEG mole-
cules onto PEG-AuNPs surface (Figure S4), as an intense 
contribution of the C1s peak at 286 eV, characteristic 
of carbon in single C–O bonds, was detected. The small 
peak, at 289 eV, was associated to the carbon atoms in the 
terminal COOH groups of the conjugated PEG molecules.60 
The single O1s peak, at 533 eV, could be correlated to 
oxygen in the C–O–C bonds typical of the PEG polymer. 
Finally, the strong decrease in the nitrogen peak was due 
to the PEG layer formation. The full screening of the sulfur 
contribution also suggested the formation of a PEG layer 
having an average thickness of the order of 10 nm. Peaks 
were assigned based on previous calibration, before and 
after PEGylation.
X-ray diffraction
The crystallinity of AuPEG_1 was confirmed by XRD 
(Figure S5). The XRD pattern of AuPEG_1 was associated 
to a crystal structure with a face-centered cubic nature.
electron microscopy
SEM images (Figure S6) demonstrated that AuPEG_1 had 
well-defined and homogeneous shape and size.
Representative TEM images of the colloidal solutions 
characterized by absorption spectroscopy are shown in 
Figure 6. PEG-AuNPs were well dispersed in size and 
shape, with an average size of 6.7±0.5 nm for AuPEG_1 
and equal to 12.5±0.5 nm for AuPEG_3, as estimated from 
350 particles on a given TEM image. However, some of the 
particles displayed a somewhat faceted shape as a result of 
their nanocrystalline nature.
Following anti-Kv11.1-pAb conjugation, AuPEG_2 
formed highly clustered aggregates (Figure 6B), probably 
due to electrostatic and steric forces among the pAb proteins 
linked to the PEG-chain grafted onto the nanoparticles’ 
surface, thus validating the data obtained by UV–Vis 
spectroscopy. Similarly, AuPEG_4 (Figure 6D) showed 
characteristic linear chain likely due to the preferential 
location of PEG or antibody molecules onto the particles, 
with a probable steric arrangement of anti-Kv11.1-pAb. It 
should be noted, however, that agglomeration could also be 
associated to artifacts arising during the preparation of TEM 
specimens, for example, due to solvent evaporation. The 
morphology of the anti-Kv11.1-pAb-targeted PEG-AuNPs 
(AuPEG_2 and AuPEG_4) (Figure 6B and D respectively), 
as revealed by TEM, was spherical and well defined with 
AuNPs of homogeneous shape.
Polarization modulation-infrared reflection-adsorption 
spectroscopy
PM-IRRAS analysis was performed on PEG-AuNPs 
immobilized on a gold surface. The PM-IRRAS spectra of 
AuPEG_2 and AuPEG_4 (Figure 7) showed the characteristic 
vibration band of the PEG molecules (C–O–C) at 1,100 cm-1 
together with the νC–O/νCOO stretching modes of the 
carboxylate groups at 1,415 cm-1. The νC=O stretching 
mode of the carboxylic group expected at 1,725 cm-1 and a 
band at 1,247 cm-1 were attributed to C–OH of DOX. The 
intense amide bands at 1,650 and 1,550 cm-1 confirmed the 
successful grafting of pAb to the PEG-AuNPs surface. In 
particular, PM-IRRAS spectra of PEG-AuNPs interacting 
with anti-Kv11-pAb (Figure 7B) showed a shift of the amide 
bond bands, probably due to a rearrangement of the system in 
the presence of the antibody. Moreover, AuPEG_4 showed 
a relevant enhancement of the intensity of the amide bond 
bands with respect to AuPEG_2 spectrum (Figure 7A). The 
area of the amide bond bands was integrated in both cases 
and was found equal to 7.6 au and 20.8 au for AuPEG_2 
and AuPEG_4, respectively. These results suggested that 
DOX loaded onto PEG-AuNPs played a key role in the steric 
arrangement of anti-Kv11.1-pAb.
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Zeta potential
The zeta potential of AuPEG_1 was found to be equal 
to -13.8±2.0 mV, suggesting the presence of free negatively 
charged carboxylic acid functions on the surface of the nano-
particles. A complete list of the zeta potential of all PEG-
AuNPs used in this study is reported in Table S2. Notably, 
all PEG-AuNPs samples were colloidally stable.
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Figure 6 representative TeM images.
Notes: representative TeM images of (A) auPeg_1, (B) auPeg_2, (C) auPeg_3, and (D) auPeg_4. scale bars: 50 nm. (E) hr-TeM image of auPeg_1 clearly showing 
a metal core of around 10 nm and suggesting the presence of an organic Peg layer of few nanometers.
Abbreviations: TeM, transmission electron microscopy; Peg, polyethylene glycol; hr-TeM, high-resolution TeM; auPeg, Peg-coated aunPs.
?????
?
?
?????????????????
????
?
????
?
????
?
????
?????
???
???
????
?
????? ????? ????? ????? ?????
Figure 7 PM-irras spectra of (A) auPeg_2 or (B) auPeg_4 immobilized onto 
a gold surface.
Abbreviations: PM-IRRAS, polarization modulation-infrared reflection-adsorption 
spectroscopy; Peg, polyethylene glycol; auPeg, Peg-coated aunPs.
nanoparticle tracking analysis
With the exception of PEG-AuNPs dispersed in FBS at 
time 0 hour, NTA showed a linear relationship between the 
increase in PEG-AuNPs hydrodynamic diameters and the 
amount of functionalities added onto the PEG-AuNPs sur-
face, with an increase in hydrodynamic diameter developing 
from nonfunctionalized AuPEG_1 to targeted, DOX-loaded 
AuPEG_4 (Table 1 and Figure S7). However, this trend was 
not detected in FBS at time 0 hour, probably due the formation 
of a “proteincorona” around nonfunctionalized PEG-AuNPs. 
Here it is thought that proteins present in FBS absorb onto 
and dissociate randomly from the surface of the AuPEG_1 
nanoparticle (“protein corona” formation), shielding the dif-
ferences in size among functionalized and nonfunctionalized 
AuNPs. NTA measurements for dispersing media (ie, PBS, 
FBS, or DMEM supplemented with 10% FBS) without PEG-
AuNPs demonstrated that these did not interfere with the 
analysis of PEG-AuNPs dispersions (Figure S8).
In general, no significant aggregation was evidenced 
over time. As regards the changes in hydrodynamic diameter 
over time in PBS, a number of possible explanations exist. 
In the case of AuPEG_1, it is most likely due to the aggre-
gation of the particles over time in the high salt-containing 
PBS solution. The exact reason for the apparent reduction 
in AuPEG_2 and AuPEG_4 hydrodynamic diameter over 
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Based on UV–Vis optical studies (Figure S10), it was estimated 
that 10 μg of DOX was loaded onto 5×10-8 mol of AuPEG_3, 
and 10.3 μg of DOX were present instead in 5×10-8 mol of 
AuPEG_4. By extrapolating the amount of DOX present in the 
PEG-AuNPs samples at a concentration equal to their LC
50
, it 
was estimated that the EC
50
 for DOX delivered by AuPEG_3 
and AuPEG_4 was equal to ~45 and 29 nM, respectively.
As a proof-of-principle experiment, molecular DOX 
was tested (Figure 8B) and its EC
50 
(equal to 1.4±0.7 μM) 
was compared to that of DOX delivered by AuPEG_3 and 
AuPEG_4. Such comparison (Figure 8D) showed that the 
PEG-AuNPs increased the chemotherapeutic effect of DOX 
against pancreatic cancer cells more than 30 times, while the 
in vitro anti-tumor efficacy of DOX was 48 times higher when 
PEG-AuNPs were actively targeted with anti-Kv11.1-pAb.
Notably, the COOH-terminated PEG constituting the 
organic component of PEG-AuNPs did not show any 
significant cytotoxicity at concentration of 67.1 μg/mL after 
24 hours of exposure (Figure S11). Since the amount of 
diacid PEG
600 
loaded onto AuPEG_1 was equal to 9 μg/mL, 
the control concentration tested for COOH-terminated PEG 
was more than seven times higher than that loaded on PEG-
AuNPs, thus demonstrating that such organic coating did not 
influence the toxic impact of the nanocarrier itself.
cell cycle
Flow cytometry was used to evaluate whether the in vitro 
activity of the DOX toward PDAC cells was maintained when 
delivered by PEG-AuNPs (Figure 9). Doxorubicin is an anti-
cancer drug that interacts with DNA, causing a G2-/M-phase 
cell-cycle arrest.62 Exposure of PANC-1 cells to AuPEG_3 
clearly showed a shift in the cell population toward G2/M 
phase at both the concentrations tested. These results dem-
onstrated that cell death triggered by AuPEG_3 was indeed 
linked to DOX activity. This was correlated with a null or 
negligible change in the cell population composition when 
PANC-1 cells were exposed to AuPEG_1 and AuPEG_2. 
Interestingly, exposure to AuPEG_4 was associated with a 
further small increase in the number of cells entering G2/M 
phase. Indeed, these data supported the EC
50
 determination 
findings and evidenced the therapeutic efficacy of the DOX 
delivered by AuPEG_3 and AuPEG_4.
Drug delivery – mechanism
cellular internalization of auPeg_3 and auPeg_4 
and colocalization into lysosomes
LSCM was used as a qualitative technique to define the 
internalization of the gold nanocarriers (AuPEG_3 and 
AuPEG_4) into PDAC cells and the release of DOX 
Table 1 average hydrodynamic diameter of Peg-aunPs 
dispersed in PBs, FBs, or complete cell medium (ie, DMeM 
supplemented with 10% FBs) before and after incubation at 37°c 
for 24 hours as determined by nTa
Sample t=0 hour (nm) t=24 hours (nm)
PBS
auPeg_1 81±10.3 127±8.0
auPeg_2 129±4.9 97±1.4
auPeg_3 130±4.5 139±3.6
auPeg_4 133±3.4 97±0.8
FBS
auPeg_1 132±2.5 123±3.7
auPeg_2 120±2.5 116±7.8
auPeg_3 112±3.0 103±6.3
auPeg_4 113±3.7 99±10.6
DMEM supplemented with 10% FBS
auPeg_1 89±5.8 97±6.6
auPeg_2 96±3.4 94±3.9
auPeg_3 92±4.4 90±4.0
auPeg_4 107±7.0 99±5.7
Note: Data are reported as mode ± standard deviation.
Abbreviations: Peg-aunPs, polyethylene glycol-gold nanoparticles; PBs, 
phosphate-buffered solution; FBS, fetal bovine serum; DMEM, Dulbecco’s Modified 
eagle’s Medium; nTa, nanoparticle tracking analysis; auPeg, Peg-coated aunPs.
time in PBS is, however, unknown. Here we suggest that 
ions in the PBS may be coordinating to the antibody over 
time, creating areas where the electrostatic charges cause 
the formation of slipping planes and subsequent nanopar-
ticle repulsion and the observed decrease in hydrodynamic 
diameter.61 On the contrary, changes in hydrodynamic 
diameter detected over time in FBS were deemed to be 
nonsignificant (Figure S7).
Interestingly, PEG-AuNPs suspensions in complete 
cell media proved to be the most stable after 24 hours of 
incubation at 37°C compared to the suspensions in PBS or 
FBS (Figure S7). In complete cell medium, a hydrodynamic 
diameter ranging between ~90 and 110 nm characterized 
PEG-AuNPs.
lc50 and ec50 determination
Flow cytometry was used to evaluate changes in the per-
centage (%) of live cells following 24 hours of exposure to 
various concentrations of PEG-AuNPs (ranging from 0 to 
2.5×10-4 M). Human PDAC cells (PANC-1 cell line) were 
used in this study.
The dose–response curves obtained (Figure 8A and 
Figure S9A–D) clearly show that the LC
50
 values decreased 
when PEG-AuNPs were loaded with DOX (LC
50
=1.0×10-4 M 
for AuPEG_1; LC
50
=1.3×10-7 M for AuPEG_3). Such decrease 
in LC
50
 was even more evident when PEG-AuNPs were 
actively targeted with anti-Kv11.1-pAb (LC
50
=8.4×10-8 M 
approximately for AuPEG_4) (Figure 8C and Figure S9E–H). 
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within the cells. After 24 hours of exposure, AuPEG_3 
and AuPEG_4 could be detected within the PANC-1 cells 
(Figure 10). In particular, numerous PEG-AuNPs were colo-
calized with the glycosylated LAMP-1 expression. LAMP-1 
is estimated to contribute, together with LAMP-2, to ~50% of 
all proteins of the lysosome membrane.63 Thus, the expression 
of LAMP-1 was used within this study as marker for identi-
fying lysosomes.64 Indeed, comparison of the PEG-AuNPs 
detection images with the images showing the colocalized 
nanoparticles evidenced that not all the PEG-AuNPs were 
found within the lysosomes.
The presence of red fluorescent DOX molecules within 
the cell’s body was also evaluated by LSCM analysis. The 
red fluorescence from DOX molecules was clearly detected 
within the cells (Figure 10), thus suggesting effective drug 
delivery and release by PEG-AuNPs. Red fluorescence from 
DOX molecules (not detectable in the untreated specimens, 
NT) appeared to be scattered not only throughout the cyto-
plasm but also over the entire cell nuclei.
cell lysis and Western blotting of laMP-1 protein 
expression
To further establish if the internalized PEG-AuNPs were indeed 
trafficked to the lysosomes, PANC-1 cells were exposed to 
AuPEG_3 and AuPEG_4 for 24 hours, lyzed, and cell lysates 
were electrophoretically separated and probed with LAMP-1 
antibody (Figure 11). Two distinct protein bands, corresponding 
to nonglycosylated and glycosylated LAMP-1, were detected 
in the lysates of untreated PANC-1 cells (NT). A significant 
decrease in the expression of non glycosylated LAMP-1protein 
was shown following exposure to AuPEG_3 or AuPEG_4.
endocytosis pathway
To define the mechanism by which PEG-AuNPs were 
internalized into PDAC cells, we investigated whether the 
cellular uptake of AuPEG_3 and AuPEG_4 was mediated 
by 1) an energy-dependent mechanism, 2) an RME, and/or 
3) by the active targeting of the Kv11.1 subunits of hERG1 
K+ channels. A cartoon schematically reporting on the 
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Figure 8 Determination of  lc50 and ec50 values.
Notes: (A) Percentage of live cells as quantified by flow cytometry after exposing PANC-1 cells to various concentrations of PEG-AuNPs (ranging from 0 to 2.5×10-4 M) 
for 24 hours. Dose–response curves are fitted to extrapolate the LC50 value of Peg-aunPs. (B) lc50 values of Peg-aunPs as extrapolated from dose–response curves. 
(C) Percentage of live cells as quantified by flow cytometry after exposing PANC-1 cells to various concentrations of DOX (ranging from 0 to 8 μM) for 24 hours. The dose-
response curve is fitted to extrapolate the EC50 value of DOX. The scale bar is not comparable to graph (A). (D) comparison among the ec50 values of doxorubicin loaded 
onto auPeg_3, auPeg_4, or tested in its molecular form (DOX). (B, D) lc50 and ec50 values are reported as mean ±95% confidence interval.
Abbreviations: Peg, polyethylene glycol; aunPs, gold nanoparticles; lc50, half-maximal lethal concentration; DOX, doxorubicin; auPeg, Peg-coated aunPs; ec50, half-
maximal effective concentration.
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Figure 9 representative Fl2-a histograms showing the effects of auPeg_1, auPeg_2, auPeg_3, and auPeg_4 on the cell cycle of Panc-1 cells after 24 hours of exposure.
Notes: analysis of cell cycle stage for g0/g1, s, and g2/M phase was made by manual gating on the Fl2-a histogram. representative Fl2-a histograms for untreated cells 
(negative control, nT) and cells exposed to 1.5 μM DOX (positive control, PT) are also shown.
Abbreviations: DOX, doxorubicin; auPeg, Peg-coated aunPs; Peg, polyethylene glycol; aunPs, gold nanoparticles.
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Figure 10 representative lscM micrographs of Panc-1 cells exposed to auPeg_3 or auPeg_4 for 24 hours.
Notes: a negative control (nT), consisting of untreated Panc-1, was included in the experimental design. cells were stained for nuclei (in blue) and for the expression of 
glycosylated LAMP-1 (in green). PEG-AuNPs were imaged in reflectance mode and are shown in white as pseudocolor. The red fluorescence of DOX was also detected. 
DOX release in the cell’s cytoplasm was evident, as well as delivery to the subcellular target (ie, Dna in the nuclei) (highlighted by arrows). Masked images clearly 
demonstrate the colocalization of Peg-aunPs with laMP-1 expression: colocalized Peg-aunPs are shown in yellow as pseudocolor. scale bars: 5 μm (63× objective lens 
coupled to digital zoom).
Abbreviations: lscM, laser scanning confocal microscopy; Peg, polyethylene glycol; aunPs, gold nanoparticles; DOX, doxorubicin; auPeg, Peg-coated aunPs.
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internalization routes of AuPEG_3 and AuPEG_4 tested is 
shown in Figure 4.
PANC-1 cells were exposed to AuPEG_3 or AuPEG_4 for 
6 hours, following pretreatment with 0.1% NaN
3
 for 3 hours. 
NaN
3
 is commonly used in vitro to inhibit cytochrome-C oxi-
dase, the last enzyme in the mitochondrial electron transport 
chain, producing a drop in intracellular ATP concentration 
and inhibiting energy-dependent endocytosis.16,65,66 Changes 
in the cytotoxic profile triggered by PEG-AuNPs internaliza-
tion (measured as changes in cell count) were recorded and 
quantified by HCSA (Figure 12). Results were then compared 
to those obtained from PANC-1 cells cultured in the absence 
of endocytosis inhibitors (-), with or without PEG-AuNPs, 
or to PANC-1 cells exposed to the inhibitor only. PANC-1 
cells exposed to AuPEG_3 showed a significant increase in 
cell count after pretreatment with NaN
3
; conversely, there 
was no detectable change in the PEG-AuNPs cytotoxicity 
when NaN
3 
pretreated PANC-1 cells were incubated with 
AuPEG_4.
Similar trend was also seen when PANC-1 cells were 
incubated at 4°C in the presence of AuPEG_3, resulting in 
an increase in cell count, compared to the same reading at 
37°C (-). Whereas the same experiment in the presence of 
AuPEG_4 did not exhibit any significant change in the cell 
viability of 4°C-treated test group compared to the (-) control 
(Figure 12). A low temperature was used here to inhibit RME, 
as an inverse relationship correlates the culturing temperature 
to RME effectiveness.67
Subsequent experimental testing with both PEG-AuNPs 
showed no influence, on the cell cytotoxicity response, 
of the incubation with, or pretreatment with, inhibitors of 
clathrin- (Pitstop® 2) and caveolae- (Filipin III) dependent 
endocytosis (Figure 12), which are two of the main RME 
pathways. Clathrin-coated pits are the primary plasma 
membrane specialization involved in the uptake of a 
wide variety of molecules by endocytosis.68 Inhibition of 
clathrin-dependent endocytosis was achieved in this study by 
Pitstop® 2. Although limitations are associated to its use due 
to the reported nonspecificity of its mode of action,69 Pitstop® 
2 causes profound inhibition of the clathrin-dependent endo-
cytosis pathway.69,70 Filipin III is known in cellular biology as 
an inhibitor of the caveolae-mediated endocytosis pathway 
in mammalian cells.71
Finally, Brefeldin A was used as an indirect inhibitor 
of the hERG1 K+ channel maturation, as it hinders the 
anterograde protein transport from the ER to the Golgi 
apparatus.72,73 As expected, a significant increase in the cell 
count was detected only when Brefeldin A–treated PANC-1 
cells were exposed to anti-Kv11.1-pAb targeted PEG-AuNPs 
(AuPEG_4) (Figure 12).
One important aspect to consider when inhibiting endocy-
tosis is to leave unaffected the F-actin cytoskeleton of the cell, 
since reorganization of the actin filaments can impact on cel-
lular uptake processes,74 leading to multiple effects occurring 
simultaneously. In our study, the F-actin filaments maintained 
their overall morphology and distribution when PANC-1 cells 
were treated with various inhibitors (Figure S12). In addition, 
incubation with the various inhibitors used in this study did 
Figure 11 expression of glycosylated/nonglycosylated laMP-1 and β-actin proteins 
in cell lysates of Panc-1 cells as untreated (nT) or exposed to auPeg_3 and 
auPeg_4 for 24 hours.
Abbreviations: auPeg, Peg-coated aunPs; Peg, polyethylene glycol; aunPs, 
gold nanoparticles.
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Figure 12 changes in cell count as detected by hcsa when Panc-1 cells were 
exposed to auPeg_3 and auPeg_4 in the absence (-) or in the presence of 
inhibitors of potential Peg-aunPs internalization pathways.
Notes: Data are shown as average ± standard error of the mean (ntests=3 and 
nreplicates=3) and are normalized to the respective negative controls (ie, untreated 
cells or cells exposed to the inhibitor without the addition of Peg-aunPs). The 
symbols *, **, and *** indicate significant changes (P,0.05, P,0.01, and P,0.001, 
respectively) compared to (-). Two-way anOVa followed by a Bonferroni posttest 
was carried out (Prism, graph-Pad software inc., la Jolla, ca, Usa). a P-value ,0.05 
was considered statistically significant.
Abbreviations: hcsa, high-content screening and analysis; Peg, polyethylene 
glycol; aunPs, gold nanoparticles; auPeg, Peg-coated aunPs; anOVa, analysis of 
variance.
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not cause any significant change in cell viability, as quantified 
by HCSA (Figure S13).
Discussion
DOX remains the first line of treatment for various cancers 
ever since its discovery in 1971. However, the severe side 
effects associated with the administration of this chemo-
therapeutic agent (such as cardiotoxicity and nephrotoxicity) 
have triggered the development of DOX nanocarriers and 
liposomal DOX (eg, Doxil®) for passive targeting of tumors. 
Although the therapeutic profile of DOX is appreciably 
improved by these formulations, their success is often dulled 
by the appearance of newer toxicity signs like palmar-
plantar erythrodysesthesia, commonly referred as hand 
foot syndrome.75 Thus, the search and design of engineered 
DOX nanocarriers with high specificity for cancer cells is 
still under research.
In this study, PEG-capped AuNPs were synthesized 
(AuPEG_1) and further conjugated to DOX (AuPEG_4) 
as therapeutic payload and anti-Kv11.1-pAb (AuPEG_2) 
for active targeting of PDAC cells, as shown in Figure 1. 
Pancreatic cancer and its most frequent form, the PDAC, 
still carry a dismal prognosis with a 5-year survival rate 
below 6%.76 Unlike other cancer diseases, where significant 
advances have been made and new treatment modalities 
developed, promising research consistently fails to translate 
new chemotherapies against PDAC into the clinical setting.77 
This study aimed at the development and PoC in vitro test-
ing of PEG-AuNPs that overcome such therapeutic gap in 
clinical oncology.
hERG1 channels were selected as biomarker based 
on increasing scientific evidence that indicates that aber-
rant hERG1 expression may be exploited for therapy 
purposes.31,43,54,78 Major limitation of hERG1-based tumor 
therapy in humans is the potential cardiotoxicity that many 
hERG1 blockers exert. However, a promising first-in-class 
compound to attempt oncologic therapy without cardiotox-
icity, based on targeting the Kv11.1 subunit of the hERG1 
channel, has been recently reported,79 thus supporting the 
targeting strategy exploited in our study.
Based on their chemical design, the PEG-AuNPs devel-
oped within this study have been categorized as nanomedi-
cines in which the drug payload is directly attached to the 
nanoparticle surface via a degradable covalent bond.80 The 
amide group linking the PEG chains to the DOX molecules 
was designed so that it could be cleaved under the desired 
conditions, that is, by a specific enzyme present in the cell’s 
lysosomes.81,82 Nowadays, it is acknowledged that the efficacy 
of chemotherapeutic drugs is in many cases hindered not 
only by dose-limiting side effects but also by poor bioavail-
ability at the disease site. In the specific case of DOX, the 
chemical structure of this chemotherapeutic agent presents 
a primary amine with a basic pK
a
. This reduces the cellular 
uptake of DOX in an acidic environment such as that of the 
tumor tissue. Indeed, the uptake of DOX at pH 6.6 is only 
half of that at neutral pH, preventing the interaction of the 
drug with its subcellular target – the DNA in the cell nuclei. 
Consequently, the only approach by which nanocarriers such 
as PEG-AuNPs could effectively enhance DOX efficacy or, 
more precisely, could decrease the drug EC
50
 is by releasing 
the drug directly into the cytoplasm. The use of stimuli–
responsive nanomedicines, such as the ones developed in 
this study, not only ensures DOX stability during transport 
but it also allows for the efficient release of the drug payload 
only when the nanocarrier reaches the target tissue and is 
internalized into the cells,83,84 thus reducing systemic side 
effects in vivo.
AuPEG_1 was produced following previously reported 
protocols that allowed controlling the nucleation and growth 
processes via the amphiphilic (dual-nature) character of the 
dicarboxylic acid–terminated PEG polymer included in the 
synthetic steps.25,85 Applying the successful concept used 
for producing Aurimune9 as template for designing our gold 
nanocarrier, the size of PEG-AuNPs was engineered to obtain 
a delivery platform with an organic/inorganic core bigger 
than 8 nm (Figure 6D), thus avoiding rapid clearance from the 
kidneys following intravenous administration.86 A PEG layer 
was also introduced to 1) prolong the nanocarrier circulation 
time, 2) avoid the reticulo–endothelial system clearance,75 
and 3) enhance the absorption and clearance of AuNPs when 
administered through intravenous injection.19 In addition, 
the gold core was kept below 20 nm, as PEGylated AuNPs 
in this size range have showed significantly higher tumor 
extravasation.87
As expected, low aggregation levels of AuNPs_1 were 
observed as a result of the repulsive interactions between 
the PEG chains present at the surface of the nanoparticles 
(Figure 5A and Table 1). The significant red-shift and 
broadening of the LSP band in the UV–Vis spectra of 
AuPEG_2 (Figure 5A) confirmed an increase in particle size 
consequent to the surface modification of PEG-AuNPs with 
pAb,88 as well as an antibody-particle interaction. The suc-
cessful pAb grafting and the covalent conjugation of DOX 
onto PEG-AuNPs, via a covalent linkage with EDC/NHS 
groups, were also confirmed by PM-IRRAS (Figure 7).59 
The formation of an amide bond is in fact evidenced by the 
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presence of broad band at 1,675 cm-1 and an additional one 
at 1,636 cm-1 (amide II). The AuPEG_2 colloidal solution 
obtained was homogenously dispersed (Figure 6C). Taking 
into account that the size of the anti-Kv11.1-pAb is ~15 nm,78 
we can estimate that the antibody stabilized the inter-particle 
distance via a double combination of electrostatic and steric 
repulsions among the various pAb proteins linked to the 
PEG-chain grafted onto the nanoparticles’ surface. It is worth 
noting that all experiments were carried out at pH 7.4, a value 
at which the amino acids constituting the anti-Kv11.1-pAb 
(pI=6.2–6.5) are equally charged. Indeed, the conjugation of 
DOX onto the PEG-AuNPs further stabilized the colloidal 
solution. This phenomenon was confirmed by TEM images 
analysis, by means of which the size of AuPEG_3 and 
AuPEG_4 as well as the presence of aggregates were evalu-
ated (Figure 6). In particular, it was observed that AuPEG_4 
were uniformly dispersed, confirming that the amphiphilic 
anti-Kv11.1-pAb-DOX-PEG layer attached to the gold core 
of the nanoparticles stabilized the nanoparticles’ suspension 
and prevented aggregation.
In general, the hydrodynamic diameters of PEG-AuNPs, 
measured by NTA, were bigger (Table 1) than their sizes as 
quantified from TEM imaging analysis (Figures 5 and 6), 
both in PBS and in complex biological media such as FBS 
and cell culture medium. In PBS, the quite large hydrody-
namic diameters (ranging from 80 to 90 nm) were most 
likely associated with the presence of a swollen organic 
PEG coating around the gold core of the nanoparticles. 
Such a large hydrodynamic diameter indeed suggested 
that although the intracellular uptake of the PEG-AuNPs 
into PDAC cells should be triggered by the specific active 
targeting of the Kv11.1 subunit of the hERG1 K+ channels 
and subsequent immobilization on the cell surface, PEG-
AuNPs internalization could not occur by diffusion through 
the pores of the targeted K+ channel. The diffusion of big 
molecules to the cell cytoplasm across the K+ channels is in 
fact prevented by a narrowing of the pore allowing only the 
passage of permeant ions,89 the size of which does not exceed 
152 pn.90 When moving in complex dispersing media, the 
large hydrodynamic diameter was attributed to the forma-
tion of a “protein corona” (Table 1), that is, the formation 
of a layer of proteins adsorbed onto the PEG-AuNPs that 
continuously exchange with the proteins in the environment. 
It should be noted that the formation of a “protein corona” 
can significantly impact on 1) the stability in circulation, 
2) the extravasation rate of nanomedicines across tumor 
vasculature (EPR effect),86 3) the efficacy of the nanocarrier 
to be internalized into the cancer cells, driving the success of 
the active-targeted delivery,91 and 4) the carrier degradation/
dissolution and drug release.92 NTA results confirmed that 
no significant aggregation occurred in complex biological 
dispersing media following 24 hours of incubation at 37°C 
(Table 1), thus suggesting that PEG-AuNPs may be stable in 
in vivo circulation following intravenous administration. Our 
data on the hydrodynamic diameter, showing values below 
200 nm in all the conditions tested (Table 1), also suggested 
that PEG-AuNPs carriers have optimal physicochemical 
properties to effectively cross leaky vasculature via the EPR 
effect,86 thus maximizing the accumulation in the tumor tis-
sue and enabling the active targeting of the PDAC cells via 
anti-Kv11.1-pAb.
PoC in vitro data acquired by flow cytometry (Figures 8 
and 9) demonstrated that PEG-AuNPs effectively exerted 
their therapeutic activity. The EC
50
 of the DOX delivered 
by PEG-AuNPs resulted in fact more than 30-fold lower 
than that of the molecular drug (Figure 8D). In particular, 
the G2-/M-phase cell-cycle arrest detected in PANC-1 cells 
exposed to AuPEG_3 and AuPEG_4 indicated that DOX 
was released from the nanocarrier and reached its subcellular 
target (intranuclear DNA). Active targeting by anti-Kv11.1-
pAb moieties induced an increase in PEG-AuNPs cytotoxic 
effect (Figure 8) and triggered an enhanced G2-/M-phase 
cell-cycle arrest (Figure 9), which was not detected following 
exposure to AuPEG_1 or AuPEG_2.
Noteworthy, the difference in LC
50
 between AuPEG_1 
and drug-loaded PEG-AuNPs (AuPEG_3 and AuPEG_4) 
was quite large, spanning from three to almost four orders of 
magnitude (Figure 8). In nanomedicine, when nanomateri-
als are used for the delivery of cytotoxic drugs, for example, 
chemotherapeutic agents, by active targeting, their own cyto-
toxicity is less important when compared to other factors such 
as delivery efficiency and drug-release profiling. Similarly to 
other pharmaceuticals, the clinical potential of the nanocarrier 
is evaluated based on a risk–benefit ratio analysis.93 Nonethe-
less, our flow cytometry data suggested that if PEG-AuNPs 
were to be used in vivo as nanocarriers, no severe cytotoxic-
ity should be elicited by either the nanomaterial itself or its 
organic PEG coating in the pancreas. This resulted to be in line 
with the nanocarrier safe-by-design approach16 adopted.
From the therapeutic point of view, the internalization 
of PEG-AuNPs in the diseased cells of interest was of criti-
cal importance in order to exert effectively their therapeutic 
activity. LSCM data (Figure 10) demonstrated not only that 
PEG-AuNPs were internalized into PANC-1 cells but also 
that AuPEG-3 and AuPEG_4 were translocated into the 
lysosomes. Additionally, LAMP-1 protein detection and 
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quantification by cell lysis and Western blotting (Figure 11) 
demonstrated that exposure to drug-loaded PEG-AuNPs 
was accompanied by changes in the levels of LAMP-1 gly-
cosylation, which is known to protect the protein itself and 
the lysosomal membranes from intracellular proteolysis.94 
Such changes could, therefore, be associated to an increased 
lysosomal function in PANC-1 cells following exposure to 
AuPEG_3 and AuPEG_4. The LSCM and Western blot-
ting results indeed suggested that DOX could be released 
as a result of the enzymatic cleavage of the amide bond, 
in agreement with the current scientific literature.81,84 The 
scattered localization of red fluorescent DOX molecules 
within the cells’ cytoplasm and nuclei (Figure 10) further 
supported this hypothesis. As an additional experimental 
evidence of the proposed mechanism, the DOX release 
profile of AuPEG_3 was evaluated at pH 7.2 and pH 4.2 
(Figure S14). Experiments at pH 4.2 were used to simulate the 
acidic environment typical of the tumor tissue. DOX release 
into aqueous environment (PBS) was almost negligible at 
both pH. An initial release of DOX (2%) was detected after 
3 hours; it remained almost unchanged even after 170 hours 
(7 days). The percentage of DOX released after 7 days was 
equal to 2.35% at pH 4.2 and 2.18% at pH 7.2. Since after 
24-hours incubation at 37°C, the hydrodynamic diameters 
of AuPEG_3 and AuPEG_4 were comparable among the 
complex dispersing media tested (Table 1 and Figure S7), 
one could hypothesize that the hydrodynamic diameter of 
PEG-AuNPs did not influence the release of the drug pay-
load in the in vitro experiments. In order to further prove 
this hypothesis, the DOX release was evaluated in DMEM 
supplemented with 10% FBS to mimic the in vitro environ-
ment (Figure S14). DOX release in DMEM was comparable 
to that in PBS. These results confirmed once again that to 
achieve significant DOX release from PEG-AuNPs, enzy-
matic activity would be necessary.
Depending on which mechanisms the cell uses to inter-
nalize the nanocarrier, its compartmentalization may vary, 
as does its biological fate and the drug release. The cell 
type and physico-chemical properties of the nanocarrier, 
such as size, shape, or surface functionalities, can affect the 
endocytosis mechanism.95,96 A selective and strategic use of 
endocytosis inhibitors was the method selected in this study 
to 1) determine the route of PEG-AuNPs internalization into 
PDAC cells and to 2) validate the hypothesis that DOX was 
released from the gold nanocarriers in the lysosomes. Our 
results showed that AuPEG_3 was internalized by clathrin-/
caveolae-independent endocytosis (Figure 12A), which 
has been previously reported as a potential internalization 
pathway for objects with size around 90 nm,80 such as 
AuPEG_3 (Table 1). Although this pathway is less well 
understood than other RME mechanisms, it is known that 
clathrin-/caveolae-independent endocytosis results in the 
formation of endosomes, which eventually merge with 
lysosomes for degradation.97,98 Thus, this result was in good 
agreement with the LSCM results (Figure 10) showing 
colocalization of PEG-AuNPs with LAMP-1 expression, 
and with our hypothesis that DOX was released from the 
nanocarriers in the lysosomes. Interestingly, active targeting 
via anti-Kv11.1-pAb induced PEG-AuNPs to be internalized 
by a completely different mechanism. AuPEG_4 internal-
ization into PANC-1 cells was inhibited in fact only by 
incubation with Brefeldin A (Figure 12B), which was used 
to indirectly hinder the maturation of hERG1 K+ channels. 
During biogenesis, hERG1 polypeptides are folded and 
assembled in the ER, from where they are trafficked to the 
Golgi apparatus. Brefeldin A hinders such transport. Our 
HCSA results (Figure 12) showed that impeding hERG1 K+ 
channels maturation and, therefore, modifying the expression 
levels of such channels on the PANC-1 cell surface inhibited 
AuPEG_4 efficacy. This indeed suggested that the active tar-
geting of the Kv11.1 subunit of the hERG1 channels played a 
key role in triggering AuPEG_4 internalization into PANC-1 
cells. Again, this is in agreement with the safe-by-design 
approach to nanomedicine development.18 Since mature 
hERG1 K+ channels remain at the plasma membrane with a 
half-life of ~10 hours,99,100 we hypothesize that in our 24-hour 
experiments AuPEG_4 immobilized onto the cell membrane 
by active targeting of the Kv11.1 subunit were internalized 
into the cells during hERG1 channels degradation. In this 
phase, hERG1 channels are internalized in endocytic vesicles, 
tagged with ubiquitin, and then degraded in lysosomes,89,101 
thus making possible DOX to be released enzymatically 
from its nanocarrier. A cartoon presenting the proposed 
mechanisms of internalization of AuPEG_3 and AuPEG_4 
compared to molecular DOX is shown in Figure 13.
Conclusion
Prized for their versatility, optical properties, and safety, 
AuNPs are by far among the most advanced nanomaterials 
exploited for nanomedicine applications. In this study, we have 
shown by PoC studies that the synthesized PEG-AuNPs could 
be successfully employed as nanocarriers for delivering, in a 
stimuli–responsive manner, an effective dose of DOX to PDAC 
cells via an innovative active targeting strategy. More impor-
tantly, the delivery of DOX by nanocarriers caused its EC
50
 to 
drop by more than 30 times as compared to the free drug.
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Figure 13 The proposed mechanism of cell internalization of Peg-aunPs (auPeg_3 and auPeg_4) and drug release compared to molecular DOX are shown.
Notes: Peg-aunPs reach the cell membrane by diffusion and, in vitro, by sedimentation. Following association to cell membrane, auPeg_3 is internalized by clathrin-/
caveolae-independent endocytosis. endosomes are then merged with lysosomes, where DOX is released by the enzymatic cleavage of the amide bond through which DOX 
molecules are grafted to the Peg layer. in parallel, auPeg_4 associates to the cell surface by active targeting of the Kv11.1 subunit of the herg1 channels. Mature herg1 
K+ channels remain at the plasma membrane with a half-life of ~10 hours.99,100 During degradation, herg1 channels are internalized in endocytic vesicles, tagged with ubiquitin, 
and then degraded in lysosomes.101 here, DOX is enzymatically released from auPeg_4. Once released within the cell cytoplasm by diffusion, DOX can reach the nucleus and 
bind to target Dna. internalization of molecular DOX relies on diffusion of the drug to the target cell, the association/dissociation equilibrium to/from the cell membrane, 
and the transport from the inner to outer leaflet (and back) by flippases. AuNPs are represented by gray circles, PEG chains by the (~) symbol, DOX by purple stars, and the 
anti-Kv11.1-pab by blue triangles. “T”-shaped symbols indicate inhibitors. Please note that drawings are not to scale.
Abbreviations: Peg, polyethylene glycol; aunPs, gold nanoparticles; DOX, doxorubicin; auPeg, Peg-coated aunPs; h, hours.
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Although in vivo studies are needed to the evalu-
ate potential adverse events that would occur following 
intravenous administration of PEG-AuNPs, as well as to 
define their biodistribution and bioavailability profiles, 
this work offers an excellent opportunity to develop nano-
medicines featuring innovative targeting capability against 
PDAC, a disease for which few or no effective treatment 
options exist. 
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Figure S1 Dynamic light scattering (Dls) of Peg-aunPs.
Abbreviations: Peg-aunPs, polyethylene glycol-gold nanoparticles; auPeg, Peg-coated aunPs.
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Figure S2 schematic representation of Pegylated nanostructured surface.
Notes: (A) Gold surface modification with cysteamine by SAM process; (B) auPeg_1 immobilization via amide bond formed between activated cOOh groups (using eDc/
nhs) decorating the nanoparticles’ surface and the amine group of cysteamine.
Abbreviations: Peg, polyethylene glycol; saM, self-assembled monolayer; nhs, N-hydroxysuccinimide; eDc, N′-ethylcarbodiimidehydrochloride; aunPs, gold nano-
particles; auPeg, Peg-coated aunPs.
?? ??? ??? ???? ?? ??? ??? ???????
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Figure S3 changes in cell number when Panc-1 cells were exposed to auPeg_3 or auPeg_4 at concentration equal to their lc50 (corresponding to 1.3×10-7 M for 
auPeg_3 and 8.5×10-8 M for auPeg_4) for 3, 6, and 24 hours.
Notes: changes were detected by high-content screening and analysis (hcsa) based on nuclei counterstain. Data are shown as average ± standard error of the mean 
(nreplicates=3; ntests=2), and are normalized to the respective negative controls (nT).
Abbreviations: lc50, half-maximal lethal concentration; auPeg, Peg-coated aunPs; Peg, polyethylene glycol; aunPs, gold nanoparticles; h, hours.
international Journal of nanomedicine 2016:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
815
Peg-aunPs for the treatment of PDac
172 170 168 166 164 162 160
PEG-CE-Au
Binding energy, eV
2 
kc
ps
CE-Au
S2p
410 408 406 404 402 400 398 396 394 3
Binding energy, eV
2 
kc
ps
N1s
CE-Au
PEG-CE-Au
294 292 290 288 286 284 282 280
Binding energy, eV
20
 k
cp
s
C1s
CE-Au
PEG-CE-Au
92 90 88 86 84 82 80
Binding energy, eV
10
0 
kc
ps
Au4f
CE-Au
PEG-CE-Au
540 538 536 534 532 530 528 526 524
Binding energy, eV
20
 k
cp
s
O1s
CE-Au
PEG-CE-Au
Figure S4 XPs analysis of cysteamine gold surface before (ce-au) and after (Peg-ce-au) immobilization of pegylated gold nanoparticles.
Abbreviations: XPs, X-ray photoelectron spectroscopy; Peg, polyethylene glycol.
?????
Figure S6 representative seM image of auPeg_1 deposited on a planar gold 
surface.
Abbreviations: seM, scanning electron microscopy; auPeg, Peg-coated aunPs; 
Peg, polyethylene glycol; aunPs, gold nanoparticles.
?????
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Figure S5 XrD spectra of auPeg_1.
Notes: Diffraction peaks were detected at 2θ=22.68°, 38.41°, 43.78°, 44.86°, 
64.87°, and 77.74° which correspond to (110), (111), (200), (200), (220), and (311) 
lattice plane, respectively.
Abbreviations: XrD, X-ray diffraction; auPeg, Peg-coated aunPs; Peg, 
polyethylene glycol; aunPs, gold nanoparticles.
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Figure S7 nTa of Peg-aunPs dispersed in (A, B) PBs, (C, D) FBs, or (E, F) DMeM supplemented with 10% FBs.
Notes: Measurements were carried out (A, C, E) immediately after dispersion (t=0 hour) or (B, D, F) following 24 hours of incubation at 37°c (t=24 hours). graphs show 
the average particle concentration for sizes ranging from 0 to 700 nm. Data of control experiments (ie, dispersing media without Peg-aunPs) were subtracted and curves 
were then normalized from 0 to 1.
Abbreviations: nTa, nanoparticle tracking analysis; Peg-aunPs, polyethylene glycol-gold nanoparticles; PBs, phosphate-buffered solution; FBs, fetal bovine serum; DMeM, 
Dulbecco’s Modified Eagle’s Medium; AuPEG, PEG-coated AuNPs; h, hours.
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Figure S8 nTa of Peg-aunPs dispersed in (A, B) PBs, (C, D) FBs, or (E, F) DMeM supplemented with 10% FBs.
Notes: Measurements were carried out (A, C, E) immediately after dispersion (t=0 hour) or (B, D, F) following 24 hours of incubation at 37°c (t=24 hours). graphs show 
the average particle concentration ± standard deviation for sizes ranging from 0 to 700 nm. nTa measurements for dispersing media (ie, PBs, FBs, or DMeM supplemented 
with 10% FBs) without Peg-aunPs are also reported in each graph, showing that these did not interfere with the analysis of Peg-aunPs dispersions. (D) inset shows 
differences between nTa graphs of FBs without Peg-aunPs (in gray) and of auPeg_1 (in black). (A–F) Differences in the maximal concentration of samples are associated 
with the dilution tested and do not influence the outcome of the experiment.
Abbreviations: nTa, nanoparticle tracking analysis; Peg-aunPs, polyethylene glycol-gold nanoparticles; PBs, phosphate-buffered solution; FBs, fetal bovine serum; DMeM, 
Dulbecco’s Modified Eagle’s Medium; AuPEG, PEG-coated AuNPs; h, hours.
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Figure S9 Determination of lc50 values.
Notes: (A–D) Percentage (%) of live cells as quantified by flow cytometry after exposing PANC-1 cells to various concentrations of PEG-AuNPs (ranging from 0 to 2.5×10-4 M) 
for 24 hours. Dose–response curves are fitted to extrapolate the LC50 value of Peg-aunPs. scale bars are not comparable among the graphs. (E–H) lc50 values of Peg-
aunPs as extrapolated from dose–response curves. lc50 values are reported as mean ± 95% confidence interval.
Abbreviations: Peg-aunPs, polyethylene glycol-gold nanoparticles; lc50, half-maximal lethal concentration; auPeg, Peg-coated aunPs.
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Figure S10 UV–vis absorption spectra of DOX at increasing known concentrations.
Note: a calibration curve was extrapolated from such measurements and the amount of DOX molecules grafted onto Peg-aunPs surface was estimated based on this 
curve.
Abbreviations: DOX, doxorubicin; Peg-aunPs, polyethylene glycol-gold nanoparticles.
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Figure S11 Percentage of live cells as quantified by flow cytometry after exposing PANC-1 cells to COOH-terminated PEG (67.1 μg/ml) for 24 hours.
Notes: Values for the negative (untreated cells [nT]) and positive (cells exposed to 70% acetone for 30 minutes, PT) control are also shown for comparison. The symbol 
(***) indicates significant changes (P,0.001) as compared to the negative control. column statistics followed by a one-sample t-test analysis was carried out (nreplicates=2) 
(Prism, graph-Pad software inc., la Jolla, ca, Usa). a P-value ,0.05 was considered statistically significant.
Abbreviation: Peg, polyethylene glycol.
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Figure S12 representative confocal micrographs of Panc-1 cells cultured in the presence of inhibitors of 1) the cellular energy-dependent mechanisms of uptake (nan3) 
for 3 hours; 2) rMe pathways (4°c for 4 hours); 3) clathrin-dependent endocytosis (Pitstop® 2) for 6 hours; 4) calveolin-dependent endocytosis (Filipin iii) for 30 minutes; 
or 5) the protein transport from the endoplasmic reticulum to the golgi apparatus (Brefeldin a) for 6 hours.
Notes: a negative control (-), consisting of Panc-1 cells exposed to supplemented cell medium, was included in the experimental design. cells were stained with rhodamine 
phalloidin (F-actin, in red) and Hoechst 33342 (nuclei, in blue). No significant changes in the organization of the cytoskeleton could be detected. Scale bars: 20 μm (63× 
objective lens).
Abbreviation: rMe, receptor-mediated endocytosis.
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Figure S13 Untreated Panc-1 cytotoxicity response to inhibitors.
Notes: changes in cell count in the presence of inhibitors of 1) the cellular energy-dependent mechanisms of uptake (nan3) for 3 hours; 2) rMe pathways (4°c for 4 hours); 
3) clathrin-dependent endocytosis (Pitstop® 2) for 6 hours; 4) calveolin-dependent endocytosis (Filipin iii) for 30 minutes; or 5) the protein transport from the endoplasmic 
reticulum to the golgi apparatus (Brefeldin a) for 6 hours. a negative control (-), consisting of Panc-1 cells exposed to supplemented cell medium, was included in the 
experimental design. Cells nuclei were stained with Hoechst 33342 and counted by HCSA. No significant change in cell count could be detected, as confirmed by statistical 
analysis (two-way anOVa followed by a Bonferroni post-test) (Prism, graph-Pad software inc.). a P-value ,0.05 was considered statistically significant. Data are reported 
as average ± standard error of the mean (nreplicates=3; ntests=3) and are normalized on the (-) control.
Abbreviations: rMe, receptor-mediated endocytosis; hcsa, high-content screening and analysis; anOVa, analysis of variance.
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Figure S14 Percentage of DOX released over time from auPeg_3 into aqueous 
PBs at ph 4.2 (black squares) and at ph 7.2 (red dots).
Notes: The percentage of DOX released by auPeg_3 incubated in DMeM 
supplemented with 10% FBs was also monitored. Data are reported as average ± 
standard deviation. Release curves were fitted.
Abbreviations: Peg, polyethylene glycol; PBs, phosphate-buffered solution; FBs, 
fetal bovine serum; DMEM, Dulbecco’s Modified Eagle’s Medium; DOX, doxorubicin; 
aunPs, gold nanoparticles; auPeg, Peg-coated aunPs.
Table S1 effects of Peg-aunPs on the cell cycle of Panc-1 cells after 24 hours of exposure
Sample Concentration
(M)
G0/G1 phase S phase G2/M phase
Average SD Average SD Average SD
nT 0 51.88 0.96 12.27 0.08 31.09 1.46
auPeg_1-treated cells 1.3×10-5 51.96 0.81 13.13 0.28 28.74 0.70
1.9×10-5 52.87 0.29 13.43 0.25 28.20 1.14
auPeg_2-treated cells 1.4×10-6 55.92 0.64 12.13 0.34 27.29 1.15
2×10-6 54.13 1.74 12.82 0.57 27.98 1.80
auPeg_3-treated cells 2.5×10-8 45.01 2.21 20.78 0.34 27.35 3.01
4×10-8 43.80 0.58 20.30 0.31 30.65 0.41
auPeg_4-treated cells 2.5×10-8 39.99 2.96 19.61 0.34 32.21 1.61
4×10-8 41.04 0.11 19.66 0.28 33.73 0.80
cells exposed to free 
molecular DOX (PT)
1.5×10-6 25.58 0.37 23.16 0.56 42.79 0.21
Notes: Values for untreated (negative control [nT]) and 1.5 μM doxorubicin-treated (positive control [PT]) controls are also reported for comparison. Data are reported 
as average (nreplicates=2) ± standard deviation (sD).
Abbreviations: DOX, doxorubicin; Peg-aunPs, polyethylene glycol-gold nanoparticles; auPeg, Peg-coated aunPs.
Table S2 Zeta potential values for Peg-aunPs dispersed in PBs 
at ph 7
Sample Zeta potential  
(± standard deviation) (mV)
auPeg_1 -13.8 (±2.0)
auPeg_2 -8 (±6.0)
auPeg_3 -4 (±0.1)
auPeg_4 +12 (±3.0)
Note: all dispersions are colloidally stable.
Abbreviations: Peg-aunPs, polyethylene glycol-gold nanoparticles; PBs, phosphate-
buffered saline; auPeg, Peg-coated aunPs.
additional experiments
DOX release from Peg-aunPs
The release studies were performed at room temperature. 
AuPEG_3 were dispersed at concentration of 1.2×1012 
particles/mL in 2.0 mL PBS or DMEM supplemented with 
10% FBS in a 5 mL test tube. pH was adjusted to 7.2 or 4.2. 
The drug release study was conducted at room tempera-
ture with continuous stirring at 150 rpm. After incubation 
from 0 to 170 hours, the nanoparticles suspensions were 
centrifuged (14,000 rpm, 20 minutes) and dialyzed in PBS 
or supplemented DMEM (dialysis tubing Spectra/Por 3; 
molecular weight cut-off 3,500 Da; Serva Electrophoresis, 
Heidelberg, Germany). The amount of released DOX was 
analyzed by fluorescence spectroscopy at λ
exc
 of 489 nm. All 
measurements were carried out using LS50B fluorescence 
spectrometer (PerkinElmer, Villebon-sur-Yvette, France).
The experiments were performed twice in triplicate for each 
of the samples. The amount of DOX release was determined 
by Equation 1. The calibration curves showed very good 
linearities (R2=0.9964 at pH 4.2, R2=0.9988 at pH 7.2, and 
R2=0.9998 in supplemented DMEM) in the relevant range 
of concentrations.
 
%DOX
release
Concentration of DOX released
Initial DOX co
=
ncentration
×100
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